 |
 |
 |
|
|
|
|
|
|
|
|
||
|
|
|
|
||||||||||||||
|
|
||||||||||||||
|
|||||||||||||||
|
|
||||||||||||||
|
|
|
|
|
Investors |
| In 2005, Galenea was officially launched by the signing of a research and development collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., a multinational, multibillion dollar pharmaceutical company with proven success in developing therapies for central nervous system diseases. This collaboration is centered around screening the calcineurin pathway for novel targets for the treatment of schizophrenia. | |
|
Next Board of Directors
»
|
|
|
|||
|
|||
|